Abbott Laboratories Alinity s Blood Screening Assays - Clinical Evaluation Protocol

Not Applicable

Completed

• Conditions: Healthy
• Interventions: Device: Alinity s HBsAg and Alinity s HBsAg Confirmatory Assay; Device: Alinity s HTLV I/II Assay; Device: Alinity s Anti-HCV Assay; Device: Alinity s HIV Ag/Ab Combo Assay; Device: Alinity s Anti-HBc Assay; Device: Alinity s Chagas Assay

• Registration Number: NCT03285295
• Lead Sponsor: Abbott Diagnostics Division

Brief Summary

The objective of this study is to demonstrate the performance and intended use of each of the Alinity s investigational assays in a donor screening environment using clinical specimens to evaluate assay performance characteristics. A comparison of assay performance will be done versus the Food and Drug Administration (FDA) licensed assays. The data will be used to support regulatory submissions and/or publications.

Detailed Description

This study evaluates Alinity s investigational assays using the Alinity s System. The Alinity s System is a high-volume, automated, blood-screening analyzer that is designed to determine the presence of specific antigens and antibodies by using chemiluminescent microparticle immunoassay (CMIA) detection technology. The system performs high-throughput routine and stat processing that features continuous access and automated retesting.

The Alinity s System is used for infectious disease marker testing in blood-screening and plasma laboratories for the following assays: Anti-HBc, Anti-HCV, HTLV I/II, Chagas, HBsAg, HBsAg Confirmatory and HIV Ag/Ab Combo.

Study Timeline

• Study First Submitted: 2017-09-12
• Study First Submitted QC: 2017-09-14
• Study Start: 2017-09-15
• Study First Posted: 2017-09-18
• Primary Completion: 2018-05-23
• Study Completion: 2018-06-21
• Disposition First Submitted: 2019-05-03
• Disposition First Submitted QC: 2019-05-15
• Results First Submitted: 2019-07-12
• Status Verified: 2019-09
• Results First Submitted QC: 2019-09-17
• Last Update Submitted: 2019-09-17
• Results First Posted: 2019-10-09
• Disposition First Posted: 2019-10-09
• Last Update Posted: 2019-10-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 106881

Inclusion Criteria

• Healthy donors who consented to participate in the study.

Exclusion Criteria

• For testing with the Alinity s Chagas assay, exclude donors that have been screened on a previous donation using a licensed test for antibodies to T cruzi.

Note: A subject may participate at different times during the study for separate assay studies, but each subject should be represented only once for each assay.

The protocol does not define an age limit. A donor must be at least 17 years old to donate to the general blood supply, or 16 years old with parental/guardian consent, if allowed by state law.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Screening	Alinity s HBsAg and Alinity s HBsAg Confirmatory Assay	All subjects will be tested with at least one of the investigational Alinity s assays (Anti-HBc, Anti-HCV, HTLV I/II, Chagas, HBsAg, HBsAg Confirmatory, HIV Ag/Ab Combo) on Alinity s system.
Screening	Alinity s Anti-HBc Assay	All subjects will be tested with at least one of the investigational Alinity s assays (Anti-HBc, Anti-HCV, HTLV I/II, Chagas, HBsAg, HBsAg Confirmatory, HIV Ag/Ab Combo) on Alinity s system.
Screening	Alinity s Anti-HCV Assay	All subjects will be tested with at least one of the investigational Alinity s assays (Anti-HBc, Anti-HCV, HTLV I/II, Chagas, HBsAg, HBsAg Confirmatory, HIV Ag/Ab Combo) on Alinity s system.
Screening	Alinity s HIV Ag/Ab Combo Assay	All subjects will be tested with at least one of the investigational Alinity s assays (Anti-HBc, Anti-HCV, HTLV I/II, Chagas, HBsAg, HBsAg Confirmatory, HIV Ag/Ab Combo) on Alinity s system.
Screening	Alinity s Chagas Assay	All subjects will be tested with at least one of the investigational Alinity s assays (Anti-HBc, Anti-HCV, HTLV I/II, Chagas, HBsAg, HBsAg Confirmatory, HIV Ag/Ab Combo) on Alinity s system.
Screening	Alinity s HTLV I/II Assay	All subjects will be tested with at least one of the investigational Alinity s assays (Anti-HBc, Anti-HCV, HTLV I/II, Chagas, HBsAg, HBsAg Confirmatory, HIV Ag/Ab Combo) on Alinity s system.

Primary Outcome Measures

Name	Time	Method
Alinity s Anti-HCV Assay Specificity	10 months	Total of 16,999 serum and plasma specimens from whole blood donors as well as plasmapheresis specimens were tested with Alinity s Anti-HCV assay. Repeatedly reactive specimens were tested further with supplemental assays, if required.
Alinity s HBsAg Assay Specificity	10 months	Total of 16993 serum and plasma specimens from whole blood donors as well as plasmapheresis specimens were tested with Alinity s HBsAg Assay. Repeatedly reactive specimens were further tested with Alinity s HBsAg Confirmatory and supplemental assays, if required.
Alinity s HBsAg and HBsAg Confirmatory Assay Sensitivity	10 months	Total of 432 specimens from subjects known to be HBsAg positive were tested with Alinity s HBsAg and HBsAg Confirmatory assay.
Alinity s HTLV I/II Assay Specificity	10 months	Total of 15877 serum and plasma specimens from whole blood donors specimens were tested with Alinity s HTLV I/II Assay. Repeatedly reactive specimens were further tested with Alinity s HTLV I/II and supplemental assays, if required.
Alinity s HTLV I/II Assay Sensitivity	10 months	Total of 706 specimens from subjects known to be HTLV positive were tested with Alinity s HTLV I/II assay. The population consists of the following: Anti-HTLV I Positive n = 461 Anti-HTLV II positive n = 141 Anti-HTLV III positive - Undifferentiated n = 4 Individual with HTLV I/II Associated Diseases n = 100
Alinity s Anti-HCV Assay Sensitivity	10 months	Total of 402 specimens from subjects known to be Anti-HCV positive were tested with Alinity s Anti-HCV assay.
Alinity s HIV Ag/Ab Combo Assay Specificity	10 months	Total of 16996 serum and plasma specimens from whole blood donors as well as plasmapheresis specimens were tested with Alinity s HIV Ag/Ab Combo Assay. Repeatedly reactive specimens were further tested with supplemental assays, if required.
Alinity s HIV Ag/Ab Combo Assay Sensitivity	10 months	Total of 1336 specimens from subjects known to be HIV-1/2 positive were tested with Alinity s HIV Ag/Ab Combo assay.
Alinity s Anti-HBc Assay Specificity	10 months	Total of 15877 serum and plasma specimens from whole blood donor specimens were tested with Alinity s Anti-HBc Assay. Repeatedly reactive specimens were further tested with supplemental assays, if required.
Alinity s Anti-HBc Assay Sensitivity	10 months	Total of 404 specimens from individuals with hepatitis B infection were tested with investigational Alinity s Anti-HBc assay. The population consists of the following: Acute Hepatitis B infection n = 28 Chronic Hepatitis B infection n = 97 Recovered Hepatitis B infection n = 279
Alinity s Chagas Assay Specificity	10 months	Total of 15804 serum and plasma specimens from whole blood donors specimens were tested with Alinity s Chagas Assay. Repeatedly reactive specimens were further tested with Alinity s Chagas and supplemental assays, if required.
Alinity s Chagas Assay Sensitivity	10 months	Total of 320 specimens from subjects known to be Chagas positive were tested with investigational Alinity s Chagas assay.

Secondary Outcome Measures

Name	Time	Method
Alinity s HBsAg Assay Increased Risk of HBV Infection	10 months	Total of 403 specimens from subjects known to be at increased risk for HBV infection were tested with investigational Alinity s HBsAg assay.; Sensitivity and Specificity not applicable.
Alinity s HBsAg Assay Recovered HBV Infection	10 months	Total of 51 specimens from subjects classified as recovered HBV infection were tested with investigational Alinity s HBsAg assay.; Sensitivity/Specificity calculation for this population not applicable.
Alinity s HTLV Assay Increased Risk of HTLV Infection	10 months	Total of 502 specimens from subjects known to be at increased risk for HTLV I/II infection were tested with investigational Alinity s HTLV I/II assay.; Sensitivity and Specificity not applicable.
Alinity s HTLV I/II Assay Endemics	10 months	Total of 509 specimens from subjects collected from areas known to be endemic for HTLV I/II infection were tested with investigational Alinity s HTLV I/II assay. Sensitivity and Specificity not applicable.
Alinity s Anti-HCV Assay Increased Risk for HCV	10 months	Total of 407 specimens from subjects known to be at increased risk for HCV infection were tested with investigational Alinity s Anti-HCV assay.
Alinity s HIV Ag/Ab Combo Assay Increased Risk of HIV-1/2	10 months	Total of 605 specimens from subjects known to be at increased risk for HIV-1/2 infection were tested with investigational Alinity s HIV Ag/Ab Combo assay.; Sensitivity and Specificity not applicable.
Alinity s HIV Ag/Ab Combo Assay Endemics	10 months	Total of 535 specimens from subjects collected from areas known to be endemic for HIV infection were tested with investigational Alinity s HIV Ag/Ab Combo assay.
Alinity s Anti-HBc Assay Increased Risk for HBV	10 months	Total of 403 specimens from subjects known to be at increased risk for HBV infection were tested with investigational Alinity s Anti-HBc assay.
Alinity s Chagas Assay Endemics	10 months	Total of 615 specimens from subjects collected from areas known to be endemic for Chagas infection were tested with investigational Alinity s Chagas assay

Trial Locations

Locations (5)

Biotest Pharmaceuticals Corporation; 🇺🇸 Boca Raton, Florida, United States

CSL Plasma Inc.; 🇺🇸 Knoxville, Tennessee, United States

QualTex Laboratories; 🇺🇸 San Antonio, Texas, United States

American Red Cross National Testing Laboratory; 🇺🇸 Saint Louis, Missouri, United States

Bloodworks Northwest; 🇺🇸 Renton, Washington, United States